A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Study Overview
=================
Brief Summary
-----------------
The efficacy of the allogeneic cell-therapy product MesenCure in addition to standard of care will be evaluated in comparison to placebo control in 300 moderate to severe Covid patients

Official Title
-----------------
A Controlled Study to Evaluate the Efficacy of Allogeneic MesenCure for the Treatment of Patients With ARDS

Conditions
-----------------
ARDS

Intervention / Treatment
-----------------
* Biological: MesenCure
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients are able and agree to sign informed consent form before any study-specific procedure. Males or females, age range 18-80. Documented ARDS RA-O2 Saturation of ≤93% and/or Evidence of COVID19-related pulmonary infiltrates on chest X-ray/thoracic tomography Stable hemodynamic condition (blood pressure of systolic <180mm Hg and diastolic <110mm Hg) Exclusion Criteria: General: Pregnant or breast-feeding females. History of drug abuse. Heavy smokers (above 2 packages a day). Subjects incapable of giving consent. Background medical conditions: Known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation. History of advanced congestive heart failure or active acute myocardial infarction (AMI), renal failure (estimated GFR of <30 ml/min/1.73 m2 at screening), or hepatic disease (hepatic insufficiency classified as Child-Pugh B or C). Known autoimmune diseases. Received any investigational drug within 30 days prior to screening day (Visit 1) (Remdesivir is not considered investigational, and is not an exclusion criteria). Immunocompromised condition from any reason, at screening. Abnormal clinically significant laboratory test findings, as per the investigator's judgment. Poorly controlled diabetic subjects (HbA1c > 9%). Known active lung malignancy. Concomitant treatment: Currently treated with Immunosuppressive agents other than corticosteroids used for treating COVID19. Treatment for cancer (i.e. chemotherapy or radiotherapy treatment) within the last 12 months. Hypersensitivity: Known history of hypersensitivity to Dextran-40. Known history of hypersensitivity to Human Serum Albumin.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment<br> | Biological: MesenCure<br>* Enhanced mesenchymal cell-based product<br>|
| Placebo Comparator: control<br> | Other: Placebo<br>* Saline<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality |  | 1 month | 
| CRP reduction | Blood CRP is measured in mg/dL | 14 days | 
| Invasive ventilation |  | 1 month |